<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ADOXA- doxycyclineÂ capsuleÂ </strong><br>PharmaDerm a division of Fougera Pharmaceuticals Inc.<br></p></div>
<h1>ADOXA<span class="Sup">Â®</span><span> DOXYCYCLINE CAPSULES, USP</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>To reduce the development of 
drug-resistant bacteria and maintain the effectiveness of doxycycline capsules and other antibacterial drugs, 
doxycycline capsules should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="de1"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">
Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
Doxycycline 150 mg capsules contain doxycycline monohydrate equivalent to 150 mg of
doxycycline for oral administration. Inactive ingredients include colloidal silicon dioxide, FD&amp;C
Red #40, FD&amp;C Yellow #6, gelatin, magnesium stearate, microcrystalline cellulose, sodium
starch glycolate, and titanium dioxide. Its molecular weight is 462.46. The chemical designation
of the light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline.

</p>
<p>Structural formula:</p>
<div class="Figure"><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0cecc43f-cc40-4c48-9e43-ae8d77af4e49&amp;name=adoxa-01.jpg"></div>
<p>C<span class="Sub">22</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">8</span>â€¢H<span class="Sub">2</span>O</p>
<p>Doxycycline has a high degree of lipid solubility and a low affinity for 
calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Tetracyclines are readily absorbed and are bound to plasma proteins in varying degrees. They are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form. Doxycycline is virtually completely absorbed after oral administration.</p>
<p>Following a 200 mg dose of doxycycline monohydrate, 24 normal adult volunteers averaged the following serum concentration values:</p>
<table frame="void">
<col align="left" width="114px">
<col align="left" width="47px">
<col align="left" width="47px">
<col align="left" width="47px">
<col align="left" width="47px">
<col align="left" width="47px">
<col align="left" width="47px">
<col align="left" width="47px">
<col align="left" width="47px">
<col align="left" width="47px">
<col align="left" width="47px">
<col align="left" width="47px">
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Rrule" align="left" valign="middle">Time (hr): </td>
<td class="Botrule Rrule" align="left" valign="middle"> 0.5 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 1.0 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 1.5 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 2.0 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 3.0 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 4.0 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 8.0 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 12.0 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 24.0 </td>
<td class="Botrule Rrule" align="left" valign="middle"> 48.0 </td>
<td class="Botrule" align="left" valign="middle"> 72.0 </td>
</tr>
<tr class="Last" valign="top">
<td class="Rrule" align="left" valign="middle"> Conc:(mcg/mL) </td>
<td class="Rrule" align="left" valign="middle"> 1.02 </td>
<td class="Rrule" align="left" valign="middle"> 2.26 </td>
<td class="Rrule" align="left" valign="middle"> 2.67 </td>
<td class="Rrule" align="left" valign="middle"> 3.01 </td>
<td class="Rrule" align="left" valign="middle"> 3.16 </td>
<td class="Rrule" align="left" valign="middle"> 3.03 </td>
<td class="Rrule" align="left" valign="middle"> 2.03 </td>
<td class="Rrule" align="left" valign="middle"> 1.62 </td>
<td class="Rrule" align="left" valign="middle"> 0.95 </td>
<td class="Rrule" align="left" valign="middle"> 0.37 </td>
<td align="left" valign="middle"> 0.15 </td>
</tr>
</tbody>
</table>
<table frame="void">
<caption><span>Average Observed Values</span></caption>
<col align="left" width="319px">
<col align="left" width="319px">
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Rrule" align="left" valign="middle"> Maximum Concentration </td>
<td class="Botrule" align="left" valign="middle"> 3.61 mcg/mL (Â± 0.9 sd) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"> Time of Maximum Concentration </td>
<td class="Botrule" align="left" valign="middle"> 2.60 hr (Â± 1.10 sd) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"> Elimination Rate Constant </td>
<td class="Botrule" align="left" valign="middle"> 0.049 per hr (Â± 0.030 sd) </td>
</tr>
<tr class="Last" valign="top">
<td class="Rrule" align="left" valign="middle"> Half-Life </td>
<td align="left" valign="middle"> 16.33 hr (Â± 4.53 sd) </td>
</tr>
</tbody>
</table>
<p>Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with normal function (creatinine clearance about 75 mL/min). This percentage excretion may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> as low as 1 to 5%/72 hours in individuals with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (creatinine clearance below 10 mL/min). Studies have shown no significant difference in serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>Hemodialysis does not alter serum half-life.</p>
<p><span class="Bold">

                        Microbiology
                     
              </span>: The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. The tetracyclines, including doxycycline, have a similar antimicrobial spectrum of activity against a wide range of gram-positive and gram-negative microorganisms. Cross-resistance of these microorganisms to tetracyclines is common.</p>
<p>Doxycycline has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#i2">INDICATIONS AND USAGE</a></span> section. </p>
<p><span class="Bold">Aerobic Gram-Positive Microorganisms:</span></p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of gram-positive microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended:</p>
<p><span class="Italics">Bacillus anthracis</span></p>
<p><span class="Italics">Listeria monocytogenes</span></p>
<p><span class="Italics">Staphylococcus aureus*</span></p>
<p>*Doxycycline is not the drug of choice in the treatment of any type of <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infection</span>.</p>
<p>Up to 44 percent of <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pyogenes</span> and 74 percent of <span class="Italics">Streptococcus faecalis</span> have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used to treat <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span> unless the microorganism has been demonstrated to be susceptible.</p>
<p><span class="Italics">Streptococcus pneumoniae </span></p>
<p><span class="Bold">Aerobic Gram-Negative Microorganisms:</span><br><span class="Italics">Bartonella bacilliformis </span><br><span class="Italics">Brucella species </span><br><span class="Italics">Calymmatobacterium granulomatis </span><br><span class="Italics">Campylobacter fetus </span><br><span class="Italics">Francisella tularensis </span><br><span class="Italics">Haemophilus ducreyi </span><br><span class="Italics">Haemophilus influenzae </span><br><span class="Italics">Neisseria gonorrhoeae </span><br><span class="Italics">Vibrio cholerae </span><br><span class="Italics">Yersinia pestis </span></p>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of gram-negative microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended:</p>
<p><span class="Italics">Acinetobacter species </span><br><span class="Italics">Enterobacter aerogenes </span><br><span class="Italics">Escherichia coli </span><br><span class="Italics">Klebsiella species </span><br><span class="Italics">Shigella species </span></p>
<p><span class="Bold">Anaerobic Microorganisms:</span><br><span class="Italics">Actinomyces israelii </span><br><span class="Italics">Clostridium species </span><br><span class="Italics">Fusobacterium fusiforme </span></p>
<p><span class="Bold">Other Microorganisms:</span><br><span class="Italics">Borrelia recurrentis </span><br><span class="Italics">Chlamydia psittaci </span><br><span class="Italics">Chlamydia trachomatis </span><br><span class="Italics">Mycoplasma pneumoniae </span><br><span class="Italics">Rickettsiae </span><br><span class="Italics">Treponema pallidum </span><br><span class="Italics">Treponema pertenue </span></p>
<p><span class="Bold">Susceptibility Tests: </span></p>
<p><span class="Bold Underline">Dilution techniques: </span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICâ€™s). These MICâ€™s provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICâ€™s should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1</span><span class="Sup">,3</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of tetracycline powder. The MIC values should be interpreted according to the following criteria for indicated aerobic microorganisms other than <span class="Italics">Haemophilus</span> species, <span class="Italics">Neisseria gonorrhoeae, </span>and<span class="Italics"> Streptococcus pneumoniae: </span></p>
<table frame="void">
<col align="left" width="319px">
<col align="left" width="319px">
<tfoot><tr class="First Last"><td align="left" colspan="2">
<p class="First Footnote">a. Interpretative criteria applicable only to tests performed by broth microdilution method using   Haemophilus Test Medium (HTM). <span class="Sup">1,3</span></p>
<p class="Footnote">b. Interpretative criteria applicable only to tests performed by agar dilution method using GC agar base with 1% defined growth supplement. <span class="Sup">1,3</span></p>
<p class="Footnote">c. Interpretative criteria applicable only to tests performed by broth microdilution method using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood. <span class="Sup">1,3</span></p>
</td></tr></tfoot>
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">MIC (mcg/mL)</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Interpretation</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¤4 </td>
<td class="Botrule" align="center" valign="middle"> Susceptible (S) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> 8 </td>
<td class="Botrule" align="center" valign="middle"> Intermediate (I) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¥16 </td>
<td class="Botrule" align="center" valign="middle"> Resistant (R) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> When testing <span class="Italics">Haemophilus spp.</span><span class="Sup">a</span>
</td>
<td class="Botrule" align="center" valign="middle">Â </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">MIC (mcg/mL)</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Interpretation</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¤2 </td>
<td class="Botrule" align="center" valign="middle"> Susceptible (S) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> 4 </td>
<td class="Botrule" align="center" valign="middle"> Intermediate (I) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¥8 </td>
<td class="Botrule" align="center" valign="middle"> Resistant (R) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> When testing <span class="Italics">Neisseria gonorrhoeae</span><span class="Sup">b</span>
</td>
<td class="Botrule" align="center" valign="middle"></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">MIC (mcg/mL) </span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Interpretation</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¤0.25 </td>
<td class="Botrule" align="center" valign="middle"> Susceptible (S) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> 0.5-1 </td>
<td class="Botrule" align="center" valign="middle"> Intermediate (I) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¥2 </td>
<td class="Botrule" align="center" valign="middle"> Resistant (R) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> When testing <span class="Italics">Streptococcus pneumoniae</span><span class="Sup">c</span>
</td>
<td class="Botrule" align="center" valign="middle"></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">MIC (mcg/mL) </span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Interpretation</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¤2 </td>
<td class="Botrule" align="center" valign="middle"> Susceptible (S) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> 4 </td>
<td class="Botrule" align="center" valign="middle"> Intermediate (I) </td>
</tr>
<tr class="Last" valign="top">
<td class="Rrule" align="center" valign="middle">â‰¥8 </td>
<td align="center" valign="middle"> Resistant (R) </td>
</tr>
</tbody>
</table>
<p>
A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial
compound in the blood reaches the concentrations usually achievable. A report of
â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism
is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This
category implies possible clinical applicability in body sites where the drug is physiologically
concentrated or in situations where high dosage of drug can be used. This category also
provides a buffer zone which prevents small uncontrolled technical factors from causing major
discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely
to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually
achievable; other therapy should be selected.
	    </p>
<p>Standardized susceptibility test procedures require the use of laboratory control 
microorganisms to control the technical aspects of the laboratory procedures. 
Standard tetracycline powder should provide the following MIC values:</p>
<table frame="void">
<col align="left" width="212px">
<col align="left" width="212px">
<col align="left" width="212px">
<tfoot><tr class="First Last"><td align="left" colspan="3">
<p class="First Footnote">a. Range applicable only to tests performed by broth microdilution method using <span class="Italics">Haemophilus</span> Test Medium (HTM).<span class="Sup">1,3</span></p>
<p class="Footnote">b. Range applicable only to tests performed by agar dilution method using GC agar base with 1% defined growth supplement. <span class="Sup">1,3</span></p>
<p class="Footnote">c. Range applicable only to tests performed by broth microdilution method using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood. <span class="Sup">1,3</span></p>
</td></tr></tfoot>
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Bold">Microorganism</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">MIC (mcg/mL)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Italics">Enterococcus faecalis</span></td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 29212 </td>
<td class="Botrule" align="center" valign="middle"> 8-32 </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Italics">Escherichia coli</span></td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 25922 </td>
<td class="Botrule" align="center" valign="middle"> 0.5-2 </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle">
<span class="Italics">Haemophilus influenzae</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 49247 </td>
<td class="Botrule" align="center" valign="middle"> 4-32 </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle">
<span class="Italics">Neisseria gonorrhoeae</span><span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 49226 </td>
<td class="Botrule" align="center" valign="middle"> 0.25-1 </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Italics">Pseudomonas aeruginosa</span></td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 27853 </td>
<td class="Botrule" align="center" valign="middle"> 8-32 </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Italics">Staphylococcus aureus</span></td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 29213 </td>
<td class="Botrule" align="center" valign="middle"> 0.12-1 </td>
</tr>
<tr class="Last" valign="top">
<td class="Rrule" align="left" valign="middle">
<span class="Italics">Streptococcus pneumoniae</span><span class="Sup">c</span>
</td>
<td class="Rrule" align="center" valign="middle"> ATCC 49619 </td>
<td align="center" valign="middle"> 0.12-0.5 </td>
</tr>
</tbody>
</table>
<p><span class="Bold Underline">Diffusion techniques: </span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure <span class="Sup">2,3</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 mcg tetracycline or 30 mcg doxycycline to test the susceptibility of microorganisms to doxycycline. </p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with 30 mcg tetracycline-class disk or the 30 mcg doxycycline disk should be interpreted according to the following criteria for indicated aerobic microorganisms other than <span class="Italics">Haemophilus</span> species, <span class="Italics">Neisseria gonorrhoeae</span>, and <span class="Italics">Streptococcus pneumoniae</span>: </p>
<table frame="void">
<col align="left" width="212px">
<col align="left" width="212px">
<col align="left" width="212px">
<tfoot><tr class="First Last"><td align="left" colspan="3">
<p class="First Footnote">a. Interpretative criteria applicable only 
to tests performed by disk diffusion method using a 30 mcg tetracycline-class disk and using <span class="Italics">Haemophilus</span> 
Test Medium (HTM).<span class="Sup">2,3</span></p>
<p class="Footnote">b. Interpretative criteria applicable only 
to tests performed by disk diffusion method using a 30 mcg tetracycline-class disk and using GC agar base with 1% defined growth supplement.<span class="Sup">2,3</span></p>
<p class="Footnote">c. Interpretative criteria applicable 
only to tests performed by disk diffusion method using a 30 mcg tetracycline-class disk and using Mueller-Hinton agar with 5% defibrinated sheep 
blood and incubated with 5% CO<span class="Sub">2</span>.<span class="Sup">2,3</span></p>
</td></tr></tfoot>
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">Zone Diameter (mm)</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Interpretation</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> Tetracycline </td>
<td class="Botrule Rrule" align="center" valign="middle"> Doxycycline </td>
<td class="Botrule" align="center" valign="middle"></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¥15 </td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¥14 </td>
<td class="Botrule" align="center" valign="middle"> Susceptible (S) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> 12-14 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 11-13 </td>
<td class="Botrule" align="center" valign="middle"> Intermediate (I) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¤11 </td>
<td class="Botrule Rrule" align="center" valign="middle">â‰¤10 </td>
<td class="Botrule" align="center" valign="middle"> Resistant (R) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> When testing <span class="Italics">Haemophilus spp.</span><span class="Sup">a</span>
</td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">Zone Diameter (mm) </span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Interpretation</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> tetracycline </td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">â‰¥29 </td>
<td class="Botrule" align="center" valign="middle"> Susceptible (S) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> 26-28 </td>
<td class="Botrule" align="center" valign="middle"> Intermediate (I) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">â‰¤25 </td>
<td class="Botrule" align="center" valign="middle"> Resistant (R) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> When testing <span class="Italics">Neisseria gonorrhoeae</span><span class="Sup">b</span>
</td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">Zone Diameter (mm) </span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Interpretation</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> tetracycline </td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">â‰¥38 </td>
<td class="Botrule" align="center" valign="middle"> Susceptible (S) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> 31-37 </td>
<td class="Botrule" align="center" valign="middle"> Intermediate (I) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">â‰¤30 </td>
<td class="Botrule" align="center" valign="middle"> Resistant (R) </td>
</tr>
<tr valign="top"><td align="left" colspan="3" valign="middle">
Zone diameters â‰¤19 mm may indicate a plasmid-mediated tetracycline-resistant Neisseria
gonorrhoeae (TRNG) isolate. These TRNG <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> should be confirmed by the dilution test
(MIC â‰¥16 mcg/mL). 
		  </td></tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" colspan="2" valign="middle"> When testing <span class="Italics">Streptococcus pneumoniae </span><span class="Sup">c</span>
</td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><span class="Bold">Zone Diameter (mm) </span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">Interpretation</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> tetracycline </td>
<td class="Botrule" align="left" valign="middle"></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle">â‰¥23 </td>
<td class="Botrule" align="center" valign="middle"> Susceptible (S) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"> 19-22 </td>
<td class="Botrule" align="center" valign="middle"> Intermediate (I) </td>
</tr>
<tr class="Last" valign="top">
<td class="Rrule" align="center" colspan="2" valign="middle">â‰¤18 </td>
<td align="center" valign="middle"> Resistant (R) </td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for tetracycline or doxycycline, respectively.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30 mcg tetracycline-class disk or the 30 mcg doxycycline disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<table frame="void">
<col align="left" width="159px">
<col align="left" width="159px">
<col align="left" width="159px">
<col align="left" width="159px">
<tfoot><tr class="First Last"><td align="left" colspan="4">
<p class="First Footnote">a. Range applicable only to tests 
performed by disk diffusion method using a 30 mcg tetracycline-class disk and using <span class="Italics">Haemophilus</span> Test Medium (HTM).
<span class="Sup">2,3</span></p>
<p class="Footnote">b. Range applicable only to tests performed by disk diffusion method using a 30 mcg 
tetracycline-class disk and using GC agar base with 1% defined growth supplement.<span class="Sup">2,3</span></p>
<p class="Footnote">c. Range applicable only to tests performed by disk diffusion method using a 30 mcg 
tetracycline-class disk and using Mueller-Hinton agar with 5% defibrinated sheep blood and incubated with 5% CO<span class="Sub">2</span>.<span class="Sup">2,3</span></p>
</td></tr></tfoot>
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Bold">Microorganism</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" colspan="2" valign="middle"><span class="Bold">Zone Diameter (mm)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule Rrule" align="center" valign="middle"><span class="Bold">tetracycline</span></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">doxycycline</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Italics">Escherichia coli</span></td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 25922 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 18-25 </td>
<td class="Botrule" align="center" valign="middle"> 18-24 </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Italics">Haemophilus influenzae<span class="Sup">a</span></span></td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 49247 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 14-22 </td>
<td class="Botrule" align="center" valign="middle"> --- </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle">
<span class="Italics">Neisseria gonorrhoeae</span><span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 49226 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 30-42 </td>
<td class="Botrule" align="center" valign="middle"> --- </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Italics">Staphylococcus aureus</span></td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 25923 </td>
<td class="Botrule Rrule" align="center" valign="middle"> 24-30 </td>
<td class="Botrule" align="center" valign="middle"> 23-29 </td>
</tr>
<tr class="Last" valign="top">
<td class="Rrule" align="left" valign="middle">
<span class="Italics">Streptococcus pneumoniae</span><span class="Sup">c</span>
</td>
<td class="Rrule" align="center" valign="middle"> ATCC 49619 </td>
<td class="Rrule" align="center" valign="middle"> 27-31 </td>
<td align="center" valign="middle"> --- </td>
</tr>
</tbody>
</table>
<p><span class="Bold Underline">Anaerobic techniques</span>:</p>
<p>For anaerobic bacteria, the susceptibility to tetracycline as MICâ€™s can be determined by standardized test methods.<span class="Sup">4</span> The MIC values obtained should be interpreted according to the following criteria:</p>
<table frame="void">
<col align="left" width="319px">
<col align="left" width="319px">
<thead valign="bottom"><tr class="Last" valign="bottom">
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">MIC (mcg/mL) </span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">Interpretation</span></td>
</tr></thead>
<tbody valign="top">
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle">â‰¤4 </td>
<td class="Botrule" align="center" valign="middle"> Susceptible (S) </td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="center" valign="middle"> 8</td>
<td class="Botrule" align="center" valign="middle"> Intermediate (I) </td>
</tr>
<tr class="Last" valign="top">
<td class="Rrule" align="center" valign="middle">â‰¥16 </td>
<td align="center" valign="middle"> Resistant (R) </td>
</tr>
</tbody>
</table>
<p>Interpretation is identical to that stated above for results using dilution techniques.</p>
<p>As with other susceptibility techniques, the use of laboratory control microorganisms is required to control the technical aspects of the laboratory standardized procedures. Standardized tetracycline powder should provide the following MIC values:</p>
<table frame="void">
<col align="left" width="212px">
<col align="left" width="212px">
<col align="left" width="212px">
<tfoot><tr class="First Last"><td align="left" colspan="3"><p class="First Footnote">a. Range applicable only to tests performed by the reference agar dilution method.</p></td></tr></tfoot>
<tbody class="Headless" valign="top">
<tr class="First" valign="top">
<td class="Botrule Rrule" align="left" valign="middle"><span class="Bold">Microorganism</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
<td class="Botrule" align="center" valign="middle"><span class="Bold">MIC (mcg/mL)</span></td>
</tr>
<tr valign="top">
<td class="Botrule Rrule" align="left" valign="middle">
<span class="Italics">Bacteroides fragilis</span><span class="Sup">a</span>
</td>
<td class="Botrule Rrule" align="center" valign="middle"> ATCC 25285 </td>
<td class="Botrule" align="center" valign="middle"> 0.12-0.5 </td>
</tr>
<tr class="Last" valign="top">
<td class="Rrule" align="left" valign="middle">
<span class="Italics">Bacteroides thetaiotaomicron</span><span class="Sup">a</span>
</td>
<td class="Rrule" align="center" valign="middle"> ATCC 29741 </td>
<td align="center" valign="middle"> 8-32 </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i2"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the 
effectiveness of doxycycline capsules and other antibacterial drugs, doxycycline capsules should 
be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused 
by susceptible bacteria. When culture and susceptibility information are available, they should be considered 
in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology 
and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Doxycycline is indicated for the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<dl>
<dt>Â 
										</dt>
<dd>
										 Rocky mountain spotted <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, typhus <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and the typhus group, Q <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, rickettsialpox, and tick <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fevers</span> 
caused by <span class="Italics">Rickettsiae</span>.
									</dd>
<dt>Â 
									</dt>
<dd>
<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by <span class="Italics">Mycoplasma pneumoniae</span>.
									</dd>
<dt>Â 
										</dt>
<dd>
									Lymphogranuloma venereum caused by <span class="Italics">Chlamydia trachomatis</span>.
									</dd>
<dt>Â 
										</dt>
<dd>
									Psittacosis (ornithosis) caused by <span class="Italics">Chlamydia psittaci</span>.
									</dd>
<dt>Â 
										</dt>
<dd>
									Trachoma caused by <span class="Italics">Chlamydia trachomatis</span>, 
although the infectious agent is not always eliminated as judged by immunofluorescence.	
									</dd>
<dt>Â 
										</dt>
<dd>
	Inclusion <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by <span class="Italics">Chlamydia trachomatis</span>.									
									</dd>
<dt>Â 
									</dt>
<dd>Uncomplicated urethral, endocervical or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults 
caused by <span class="Italics">Chlamydia trachomatis</span>.
											
									</dd>
<dt>Â 
										</dt>
<dd>
										Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by <span class="Italics">Ureaplasma urealyticum</span>.
									</dd>
<dt>Â 
										</dt>
<dd>
										<span class="product-label-link" type="condition" conceptid="440637" conceptname="Relapsing fever">Relapsing fever</span> due to <span class="Italics">Borrelia recurrentis</span>.
									</dd>
</dl>
<p>Doxycycline is also indicated for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> 
caused by the following gram-negative microorganisms:
 	    </p>
<dl>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">Chancroid</span> caused by <span class="Italics">Haemophilus ducreyi</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="434271" conceptname="Plague">Plague</span> due to <span class="Italics">Yersinia pestis</span> (formerly <span class="Italics">Pasteurella pestis</span>).				
					</dd>
<dt>Â 
					  </dt>
<dd>
						Tularemia due to <span class="Italics">Francisella tularensis</span> 
(formerly <span class="Italics">Pasteurella tularensis</span>).				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="198677" conceptname="Cholera">Cholera</span> caused by 
<span class="Italics">Vibrio cholerae</span> (formerly <span class="Italics">Vibrio comma</span>).				
					</dd>
<dt>Â 
					  </dt>
<dd>
						Campylobacter fetus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by 
<span class="Italics">Campylobacter fetus</span> (formerly <span class="Italics">Vibrio fetus</span>).				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="441497" conceptname="Brucellosis">Brucellosis</span> due to <span class="Italics">Brucella</span> 
species (in conjunction with streptomycin).				
					</dd>
<dt>Â 
					  </dt>
<dd>
						Bartonellosis due to <span class="Italics">Bartonella bacilliformis</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="199726" conceptname="Granuloma inguinale">Granuloma inguinale</span> caused by <span class="Italics">
Calymmatobacterium granulomatis</span>.				
					</dd>
</dl>
<p>Because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</p>
<p>Doxycycline is indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug:</p>
<dl>
<dt>Â 
					  </dt>
<dd><span class="Italics">Escherichia coli</span></dd>
<dt>Â 
					  </dt>
<dd>
<span class="Italics">Enterobacter aerogenes </span>(<span class="Italics">formerly Aerobacter aerogenes</span>)				
					</dd>
<dt>Â 
					  </dt>
<dd><span class="Italics">Shigella species</span></dd>
<dt>Â 
					  </dt>
<dd>
<span class="Italics">Acinetobacter</span> species (formerly <span class="Italics">Mima</span> 
species and <span class="Italics">Herellea</span> species)				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory tract infections</span> caused by 
<span class="Italics">Haemophilus influenzae</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						Respiratory tract and <span class="product-label-link" type="condition" conceptid="4056621" conceptname="Recurrent urinary tract infection">urinary infections</span> 
caused by <span class="Italics">Klebsiella</span> species.				
					</dd>
</dl>
<p>Doxycycline is indicated for treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infections</span> caused by <span class="Italics">Streptococcus pneumoniae</span> (formerly <span class="Italics">Diplococcus pneumoniae</span>).</p>
<dl>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory infections</span> caused by <span class="Italics">Streptococcus pneumoniae</span> (formerly
<span class="Italics">Diplococcus pneumoniae</span>).				
					</dd>
<dt>Â 
					  </dt>
<dd>
						Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics">Staphylococcus aureus</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">Anthrax</span> due to <span class="Italics">Bacillus anthracis</span>, 
including inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure); to reduce the incidence or progression of disease following exposure to 
aerosolized <span class="Italics">Bacillus anthracis</span>.				
					</dd>
</dl>
<p>Doxycycline is not the drug of choice in the treatment of any type of <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">staphylococcal infections</span>.</p>
<p>When penicillin is contraindicated, 
doxycycline is an alternative drug in the treatment of the following <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:</p>
<dl>
<dt>Â 
					  </dt>
<dd>
						Uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> caused by <span class="Italics">Neisseria gonorrhoeae</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">Syphilis</span> caused by <span class="Italics">Treponema pallidum</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						Yaws caused by <span class="Italics">Treponema pertenue</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="438059" conceptname="Listeriosis">Listeriosis</span> due to <span class="Italics">Listeria monocytogenes</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						Vincentâ€™s <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Fusobacterium fusiforme</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">Actinomycosis</span> caused by <span class="Italics">Actinomyces israelii</span>.				
					</dd>
<dt>Â 
					  </dt>
<dd>
						<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by <span class="Italics">Clostridium</span> species. 				
					</dd>
</dl>
<p>In acute intestinal <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span>, doxycycline may be a useful adjunct to amebicides.</p>
<p>In severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, doxycycline may be useful adjunctive therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in persons who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the tetracyclines.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="w2"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN).This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. <span class="product-label-link" type="condition" conceptid="4131814" conceptname="Enamel hypoplasia">Enamel hypoplasia</span> has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP, EXCEPT FOR <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">ANTHRAX</span>, INCLUDING INHALATIONAL <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">ANTHRAX</span> (POST-EXPOSURE), UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C</span>. <span class="Italics">difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p>All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.</p>
<p>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.</p>
<p>The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="pc1"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold">General:</span></p>
<p>As with other antibiotic preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, the antibiotic should be discontinued and appropriate therapy instituted.</p>
<p>Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span> in adults have been reported in individuals receiving tetracyclines. These conditions disappeared when the drug was discontinued.</p>
<p>Incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy when indicated.</p>
<p>Prescribing doxycycline capsules in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.1"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">All patients taking doxycycline should be advised:</p>
<p>â€“to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">phototoxicity</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, etc.) occurs. Sunscreen or sunblock should be considered. (See <span class="Bold"><a href="#w2">WARNINGS</a></span>.)</p>
<p>â€“to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration. (See <span class="Bold"><a href="#ar1">ADVERSE REACTIONS</a></span>.)</p>
<p>â€“that the absorption of tetracyclines is reduced when taken with foods, especially those which contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk. (See <span class="Bold"><a href="#di1">Drug Interactions</a></span>.)</p>
<p>â€“that the absorption of tetracyclines is reduced when taking bismuth subsalicylate. (See <span class="Bold"><a href="#di1">Drug Interactions</a></span>.)</p>
<p>â€“not to use outdated or poorly stored doxycycline.</p>
<p>â€“that the use of doxycycline might increase the incidence of <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
<p>Patients should be counseled that antibacterial drugs including doxycycline should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When doxycycline is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by doxycycline or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.2"></a><p></p>
<h2>Laboratory Tests:</h2>
<p class="First">In venereal disease when coexistent <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> is suspected, a dark-field examination should be done before treatment is started and the blood serology repeated monthly for at least four months.</p>
<p>In long-term therapy, periodic laboratory evaluations of organ systems, including hematopoietic, renal, and hepatic studies should be performed.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="di1"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Because tetracyclines have been shown to depress plasma <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</p>
<p>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.</p>
<p>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.</p>
<p>Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.</p>
<p>The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.</p>
<p>Concurrent use of tetracycline may render oral contraceptives less effective.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions:</h2>
<p class="First">False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis and Mutagenesis and Impairment of Fertility:</h2>
<p class="First">Long-term studies in animals to evaluate the carcinogenic potential of doxycycline have not been conducted.
                However, there has been evidence of oncogenic activity in rats in studies with related antibiotics, oxytetracycline (adrenal and pituitary tumors) and minocycline (<span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumors</span>). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in <span class="Italics">in vitro</span> mammalian cell assays have been reported for related antibiotics (tetracycline, oxytetracycline). Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy: Teratogenic Effects. Pregnancy Category D:</h2>
<p class="First">There are no adequate and well-controlled studies on the use of doxycycline in pregnant short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for treatment of <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk. <span class="Sup">a</span></p>
<p>A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. (Sixty-three (0.19%) of the controls and 56 (0.30%) of the cases were treated with doxycycline.) This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (i.e., in the second and third months of gestation) with the exception of a marginal relationship with <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defect</span> based on only two exposed cases. <span class="Sup">b</span></p>
<p>A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age. <span class="Sup">c</span></p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.7"></a><p></p>
<h2>Labor and Delivery:</h2>
<p class="First">The effect of tetracyclines on labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines, including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated; however, the effects of prolonged exposure to doxycycline in breast milk are unknown.<span class="Sup">d</span> Because of the potential for adverse reactions in nursing infants from doxycycline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. (See <span class="Bold"><a href="#w2">WARNINGS</a></span>.) </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <span class="Bold"><a href="#w2">WARNINGS</a></span> and <span class="Bold"><a href="#da1">DOSAGE AND ADMINISTRATION</a></span> sections.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ar1"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Due to oral doxycyclineâ€™s virtually complete absorption, side effects to the lower bowel, particularly <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and inflammatory lesions (with monilial overgrowth) in the anogenital region. Hepatotoxicity has been reported<span class="Sup">(b)(4).</span>These reactions have been caused by both the oral and parenteral administration of tetracyclines. Rare instances of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcerations</span> have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline class. Most of these patients took medications immediately before going to bed. (See <span class="Bold"><a href="#da1">DOSAGE AND ADMINISTRATION</a></span>.) </p>
<p><span class="Bold">Skin: </span>Maculopapular and erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> have been reported. <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span> has been reported but is uncommon. <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span> is discussed above. (See <span class="Bold"><a href="#w2">WARNINGS</a></span>.) </p>
<p><span class="Bold">Renal toxicity: </span>Rise in BUN has been reported and is apparently dose related. (See <span class="Bold"><a href="#w2">WARNINGS</a></span>.) </p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>: </span><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4101602" conceptname="Henoch-Schonlein purpura">anaphylactoid purpura</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, and exacerbation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
<p><span class="Bold">Blood: </span><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported with tetracyclines.</p>
<p><span class="Bold">Other: </span>Bulging fontanels in infants and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> in adults. (See <span class="Bold"><a href="#pc1">PRECAUTIONS-General</a></span>.) </p>
<p>When given over <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland. No abnormalities of thyroid function are known to occur.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life, and it would not be of benefit in treating cases of overdosage.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="da1"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.</p>
<p><span class="Bold">Adults: </span>The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours or 50 mg every 6 hours) followed by a maintenance dose of 100 mg/day. The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (particularly chronic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the urinary tract), 100 mg every 12 hours is recommended.</p>
<p><span class="Bold">For pediatric patients above eight years of age: </span>The recommended dosage schedule for pediatric patients weighing 100 pounds or less is 2 mg/lb of body weight divided into two doses on the first day of treatment, followed by 1 mg/lb of body weight given as a single daily dose or divided into two doses, on subsequent days. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> up to 2 mg/lb of body weight may be used. For pediatric patients over 100 pounds the usual adult dose should be used.</p>
<p><span class="Bold">Uncomplicated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in adults (except anorectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in men): </span>100 mg, by mouth, twice a day for 7 days. As an alternate single visit dose, administer 300 mg stat followed in one hour by a second 300 mg dose.</p>
<p><span class="Bold">Acute epididymo-<span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span> caused by <span class="Italics">N</span>. <span class="Italics">gonorrhoeae</span>: </span>100 mg, by mouth, twice a day for at least 10 days.</p>
<p><span class="Bold">Primary and <span class="product-label-link" type="condition" conceptid="437787" conceptname="Secondary syphilis">secondary syphilis</span>: </span>300 mg a day in divided doses for at least 10 days.</p>
<p><span class="Bold">Uncomplicated urethral, endocervical, or rectal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults caused by <span class="Italics">Chlamydia trachomatis</span></span>: 100 mg, by mouth, twice a day for at least 7 days.</p>
<p><span class="Bold">Nongonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> caused by <span class="Italics">C. trachomatis and U. urealyticum</span>: </span>100 mg, by mouth, twice a day for at least 7 days.</p>
<p><span class="Bold">Acute epididymo-<span class="product-label-link" type="condition" conceptid="4171915" conceptname="Orchitis">orchitis</span> caused by <span class="Italics">C. trachomatis</span>: </span>100 mg, by mouth, twice a day for at least 10 days.</p>
<p><span class="Bold">Inhalational <span class="product-label-link" type="condition" conceptid="438960" conceptname="Anthrax">anthrax</span> (post-exposure): </span></p>
<p>ADULTS: 100 mg of doxycycline, by mouth, twice a day for 60 days.</p>
<p>CHILDREN: weighing less than 100 pounds (45 kg): 1 mg/lb (2.2 mg/kg) of body weight, by mouth, twice a day for 60 days. Children weighing 100 pounds or more should receive the adult dose.</p>
<p>When used in <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, therapy should be continued for 10 days.</p>
<p>Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See <span class="Bold"><a href="#ar1">ADVERSE REACTIONS</a></span>.) If <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span> occurs, doxycycline may be given with food. Ingestion of a high fat meal has been shown to delay the time to peak plasma concentrations by an average of one hour and 20 minutes. However, in the same study, food enhanced the average peak concentration by 7.5% and the area under the curve by 5.7%. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">
Doxycycline Capsules 150 mg have a peach opaque cap printed â€œADOXA<span class="Sup">Â®</span>â€? in black ink/peach
opaque body printed â€œ150 mgâ€? in black ink. Each capsule contains doxycycline monohydrate
equivalent to 150 mg of doxycycline. They are supplied as follows:
<br><br>
Bottle of 60 NDC 10337-815-06

	    </p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">DISPENSE IN A TIGHT LIGHT RESISTANT CONTAINER AS DEFINED IN THE USP/NF.</span></p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12"></a><p></p>
<h1>ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY</h1>
<p class="First">Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO4, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO4, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.</p>
<p>Minocycline, tetracycline PO4, methacycline, doxycycline, tetracycline base, oxytetracycline HCl and tetracycline HCl were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> with high radioiodine uptake in rats fed a relatively high iodine diet.</p>
<p>Treatment of various animal species with this class of drugs has also resulted in the induction of <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">thyroid hyperplasia</span> in the following: in rats and dogs (minocycline), in chickens (chlortetracycline) and in rats and mice (oxytetracycline). Adrenal gland <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> has been observed in goats and rats treated with oxytetracycline.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>M7-A7. <span class="Italics">Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard - 7th edition.</span> Clinical and Laboratory Standards Institute (Formerly NCCLS), Wayne, PA; 2006</li>
<li>M2-A9. <span class="Italics">Performance standards for antimicrobial disk susceptibility Tests; Approved standard - 9th edition. </span>Clinical and Laboratory Standards Institute (Formerly NCCLS), Wayne, PA; 2006.</li>
<li>M100-S17. <span class="Italics">Performance standards for antimicrobial susceptibility testing; 17th informational supplement. </span>Clinical and Laboratory Standards Institute (Formerly NCCLS), Wayne, PA; 2007.</li>
<li>M11-A7. <span class="Italics">Methods for antimicrobial susceptibility testing of anaerobic bacteria; Approved standard - 7th edition.</span>Clinical and Laboratory Standards Institute (Formerly NCCLS), Wayne, PA; 2007.</li>
</ol>
<ol class="LittleAlpha">
<li>Friedman JM and Polifka JE. <span class="Italics">Teratogenic Effects of Drugs. A Resource for Clinicians (TERIS).</span> Baltimore, MD: The Johns Hopkins University Press: 2000: 149-195.</li>
<li>Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. <span class="Italics">Obstet Gynecol</span> 1997; 89: 524-528. </li>
<li>Horne HW Jr. and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. <span class="Italics">Int J Fertil</span> 1980; 25: 315-317.</li>
<li>Hale T. <span class="Italics">Medications and Mothers Milk</span>. 9th edition. Amarillo, TX: Pharmasoft Publishing 2000; 225-226.  </li>
</ol>
<p class="First"><span class="Bold">Manufactured by:</span></p>
<p><span class="Bold">PharmaDerm<span class="Sup">Â®</span></span></p>
<p>A division of Fougera Pharmaceuticals Inc.</p>
<p>Melville, NY 11747 USA</p>
<p><span class="Bold">Manufactured by:</span></p>
<p><span class="Bold">PAR PHARMACEUTICAL COMPANIES, INC.</span></p>
<p>Spring Valley, NY 10977 USA</p>
<p>IL221C</p>
<p>R02/12</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s57"></a><a name="section-14"></a><p></p>
<br><br><p class="First"><span class="Bold">PACKAGE LABEL- PRINCIPAL DISPLAY PANEL</span></p>
<p>
						NDC 10337-815-06
						<br>60 CAPSULES<br><span class="Bold">ADOXA<span class="Sup">Â®</span><br></span><span class="Bold">DOXYCYCLINE</span><br><span class="Bold">CAPSULES, USP</span><br></p>
<div class="Figure">
<a name="f04"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“
							" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0cecc43f-cc40-4c48-9e43-ae8d77af4e49&amp;name=adoxa-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ADOXAÂ 		
					</strong><br><span class="contentTableReg">doxycycline capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10337-815</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXYCYCLINE</strong> (DOXYCYCLINE ANHYDROUS) </td>
<td class="formItem">DOXYCYCLINE ANHYDROUS</td>
<td class="formItem">150Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">orange</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ADOXA;150mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10337-815-06</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065055</td>
<td class="formItem">06/01/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>PharmaDerm a division of Fougera Pharmaceuticals Inc.
							(043838424)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Par Pharmaceutical Inc. (092733690)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>26b9e8bd-a1aa-4293-aacc-927cc75149c5</div>
<div>Set id: 0cecc43f-cc40-4c48-9e43-ae8d77af4e49</div>
<div>Version: 1</div>
<div>Effective Time: 20130530</div>
</div>
</div>Â <div class="DistributorName">PharmaDerm a division of Fougera Pharmaceuticals Inc.</div></p>
</body></html>
